Developing Non-Opioid Pain Medication with Reduced Abuse Potential with Ketan Mehta Tris Pharma TRANSCRIPT
Download PDFOct 23, 2024
Ketan Mehta, Founder and CEO of Tris Pharma, is focused on developing non-addictive pain medication. Their lead drug candidate is designed to be an effective pain drug without the respiratory-depressive and addictive side effects of traditional opioid drugs. This drug works by targeting the nociceptin receptor and has...
Oct 23, 2024
Ketan Mehta, Founder and CEO of Tris Pharma, is focused on developing non-addictive pain medication. Their lead drug candidate is designed to be an effective pain drug without the respiratory-depressive and addictive side effects of traditional opioid drugs. This drug works by targeting the nociceptin receptor and has...
New Tools to Combat Prescription Opioid Abuse and Synthetic Opioid Overdoses Greg Sturmer Elysium Therapeutics TRANSCRIPT
Download PDFOct 3, 2024
Greg Sturmer, Co-Founder and CEO of Elysium Therapeutics, a company with expertise in reducing pain and addressing opioid use disorder and fatal overdose from fentanyl. Elysium has developed O2P, Oral Overdose Protection, a technology that aims to control the impact of opioids and reduce the risk of use disorder or...
Oct 3, 2024
Greg Sturmer, Co-Founder and CEO of Elysium Therapeutics, a company with expertise in reducing pain and addressing opioid use disorder and fatal overdose from fentanyl. Elysium has developed O2P, Oral Overdose Protection, a technology that aims to control the impact of opioids and reduce the risk of use disorder or...
Urging Medicare to Maintain Coverage of Skin Substitutes for Chronic Wound Care Treatments with Bill Padula and Dr. David Armstrong University of Southern California TRANSCRIPT
Download PDFSep 9, 2024
Bill Padula, PhD, Assistant Professor of Pharmaceutical and Health Economics, and Dr. David Armstrong, professor of surgery and Neurological surgery, are both at the University of Southern California and are concerned about wound care and the impact of potential changes in Medicare reimbursement of skin substitutes....